SNDX-5613 Granted FDA Fast Track Designation for the Treatment of Relapsed/Refractory Acute Leukemias

Syndax Pharmaceuticals, Inc. announced that the US FDA has granted Fast Track Designation to SNDX-5613 for the treatment of adult and pediatric patients with relapsed or refractory acute leukemias harboring a mixed lineage leukemia rearranged or nucleophosmin mutation. SNDX-5613 is the company’s highly selective, oral menin inhibitor.